Abiopharma

🔍 Meyers Steve Lawrence (Executive)

Company: OCULAR THERAPEUTIX, INC (OCUL)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 64,900 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 217,628.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 197,650 shares of Stock Option (Right to Buy) at $11.82 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: 0 | shares_owned_after: 197,650.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
• F2: Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.